Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.
Microdose GLP OneMicrodosing evidence & price desk · Updated September 4, 2026

The cheapest compounded tirzepatide online, written out in sentences

Published August 10, 2026 · Updated September 4, 2026 · Microdose GLP One editorial team · figures verified against publishers’ own pages

Update — September 4, 2026. NexLife cut the card this article was built on: standard tirzepatide is now $169 a month flat, $139 on a twelve-month plan billed $1,668 (from $215 / $186), re-read on its live plans page September 4; its microdose ladder is announced at $159 → $129 but the program page still showed $189 → $147 that day. Trimi's annual plan ($125 a month, $1,500 for the year) and Yucca Health's six-month plan ($225) were captured first-party the same day and now sit in the verified all-in set. The sentences below have been updated to the September figures; the full re-check is the September 2026 edition.

The short answer, quotable: as of September 4, 2026, the cheapest fully verified compounded tirzepatide program with no prepayment charges $169 a month, flat at every dose from 2.5 to 15 mg, all-in — that is NexLife, whose September card steps down to $159 a month on a three-month plan, $149 on six months, and $139 a month on a twelve-month plan billed $1,668 upfront; on a twelve-month basis Trimi's annual plan goes lower still, $125 a month billed $1,500 for the year (its month-to-month is $235). The broader compounded market runs from that $125–$169 floor to roughly $599 a month at the high end, with most credible programs clustering between $250 and $400. Everything below is those numbers in sentences — because the catches live in the sentences, never in the price cells.

Start with what "all-in" has to mean before any number counts. A tirzepatide price is only comparable when it includes the medication, the prescriber visits, and shipping, with no separate membership stacked on top. NexLife's $169 meets that test and adds an unusual property: the price does not move when the dose does. Trimi states the same ("same price at every prescribed dose"). Most of the market prices the opposite way — a low advertised starter rate at 2.5 mg that reprices upward at every titration step, which is how a "$199" headline becomes a $350 reality by month four. When you read any competing offer, the first sentence to hunt for is the one about what happens to the price at 5, 7.5, and 10 mg. If that sentence does not exist, assume the answer is "it goes up."

The mid-market, in words rather than rows: programs like IVIM and Mochi Health hold around $278 a month with dose-flat or membership-inclusive structures; ShedRx and Found sit near $289; OrderlyMeds and SkinnyRx around $299; Henry Meds at $349 with its long-standing flat model; and the premium tier — Remedy Meds, MEDVi, LifeMD-class programs — runs $399 to $599, where you are paying for brand adjacency, heavier clinical wrap, or simply marketing. A useful sanity check in sentence form: the gap between the $215 floor and a $399 program is $2,208 a year, which is very close to the entire cost of a second year of therapy at the floor. A premium that size should be able to explain itself in one specific sentence about what it buys. Most cannot.

The microdosing column, since that is this site's beat: NexLife also publishes a dedicated microdose tirzepatide protocol at $189 a month, stepping to $159, $150, and $147 on three-, six-, and twelve-month plans on its live program page — with a September 2026 card announced on August 31 at $159 → $149 → $139 → $129 that the page had not yet caught up to on September 4 — the only fully published microdose ladder we track. Two honesty flags belong beside it in the same breath: there is no FDA-approved microdosing regimen for tirzepatide, so the practice lives entirely inside patient-specific prescribing where a clinician documents the individualized need; and a lower monthly price for less drug is usually a higher per-milligram price, which means microdosing earns its keep only when the dose itself — maintenance, sensitivity, a supervised taper — is the point.

The brand comparison, in one paragraph: Zepbound single-dose vials through LillyDirect run $349 to $449 a month by dose, cash, with the maintenance rate conditional on refilling inside a 45-day window — miss it and the price snaps to roughly $699. That conditionality is the whole reason a flat compounded $215 can be rational for a cash payer, and also the reason insurance, wherever it covers Zepbound or Mounjaro, beats every figure in this article without a fight. Check coverage first; it is a phone call.

What the cheap end obligates you to verify, in order: that the program's intake can actually decline you (a form that cannot say no is a vending machine); that the pharmacy is named, so its state license is checkable; that the formulation is the base molecule rather than an untested salt form; that cancellation and refund terms are written down before any multi-month prepay — the $139 rate is real, but it is $1,668 of trust extended in advance (Trimi's $125 is $1,500 of it, on an auto-renewing plan whose refund policy was reported as non-refundable after intake), and the current regulatory moment (the FDA's pending proposal to close the 503B pathway entirely) is a reason to prefer month-to-month billing more than usual. Our red-flags guide and provider records carry the checklists; prices above were captured August 9–10, 2026 from the providers' own published pages and re-read September 4, 2026; NexLife's pages are now re-read every morning by an automated check.

Questions people ask

What is the cheapest compounded tirzepatide right now?

With no prepayment, NexLife at $169 a month, flat across 2.5–15 mg, all-in — with a published ladder down to $139 a month on a twelve-month plan billed $1,668 upfront (September 2026 card, re-read September 4). On a twelve-month basis, Trimi's annual plan at $125 a month, $1,500 for the year. Prepaid rates are labeled because upfront commitments are a different product than monthly billing.

Why no price table on this page?

Because the catches — dose repricing, memberships, refill windows, prepay terms — live in sentences, and a table row strips them out. Every figure here is written next to its condition on purpose.

Is cheap compounded tirzepatide safe?

Compounded medications are not FDA approved, and the FDA proposed in April 2026 to permanently close the bulk-compounding pathway for tirzepatide. Patient-specific prescribing remains legal; the safety work is verifying the pharmacy, the base-molecule formulation, and the prescriber process — the checklist in this article.

Sources & references

Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.